Sopharma AD (SPH)
- Share price (7-session average)
- 13.50 PLN+1.48% w/w
- Market cap
- PLN 6.8B
- 52-week range
- 6.04 – 15.30 PLN
Prices as of November 20, 2026, delayed.
Last updated: Source: ESEF / ESPI / GPW
Price Chart
About Sopharma AD
Sopharma is a Bulgarian pharmaceutical manufacturer - generic drugs, herbal substances, dietary supplements. Presence in 41 countries.
This description was generated with the help of AI and may contain inaccuracies. Please verify important information from official sources.
Company Details
Data sourced from GPW and OpenFIGI. Updated periodically — verify with official sources.
News
Preliminary sales revenue data for September 2026
FilingParkiet
Correction of Notification from "Kaliman RT" AD in accordance with Regulation 596/2014 for transactions with shares of "Sopharma" AD on 16.09.2026
FilingParkiet
Notification from "Kaliman RT" AD in accordance with Regulation 596/2014 for transactions with shares of "Sopharma" AD on 30.09.2026
FilingParkiet
Preliminary sales revenue data for July 2026
FilingParkiet
Notification from "Donev Investments Holding" AD in accordance with Regulation 596/2014 for a pledge of shares of "Sopharma" AD on 17.08.2026
FilingParkiet
Conclusion of a transaction under the application of Article 114, paragraph 2 of the LPOS
FilingParkiet
Communities
Frequently asked questions
- How much does a Sopharma AD share cost?
- The 7-day average share price of Sopharma AD (SPH) on GPW is 13.50 PLN.
- On which exchange is Sopharma AD listed?
- Sopharma AD is listed on GPW under the ticker SPH, ISIN: BG11SOSOBT18.
- Is Sopharma AD stock being shorted?
- Per the KNF short-selling register (as of November 22, 2026), there are no disclosed net short positions in Sopharma AD. KNF discloses positions from 0.5% of share capital, so smaller ones are not visible.
Similar companies — Pharmaceuticals
Explore the market
This information is provided for informational purposes only and does not constitute investment advice or a recommendation. Listings describe companies by the stated criteria and are not an inducement to buy or sell any financial instrument. Verify figures against official sources before making any investment decision.